Rosuvastatin + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Atherosclerosis

Conditions

Atherosclerosis

Trial Timeline

Sep 17, 2015 → Jan 29, 2019

NCT ID

NCT02546323

About Rosuvastatin + Placebo

Rosuvastatin + Placebo is a phase 3 stage product being developed by AstraZeneca for Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02546323. Target conditions include Atherosclerosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02546323	Phase 3	Completed	Sep 17, 2015	Jan 29, 2019	Atherosclerosis
NCT00929734	Phase 2	Completed	Mar 1, 2010	Jan 1, 2014	Chronic Obstructive Pulmonary Disease (COPD)
NCT00951132	Phase 2	Withdrawn	Sep 1, 2009	Dec 1, 2013	Depression
NCT00990028	Phase 1/2	Completed	Aug 1, 2009	Aug 1, 2011	Head Injury
NCT00783042	Phase 1	Completed	Oct 1, 2008	May 1, 2009	Atherosclerosis
NCT00673582	Approved	Terminated	Apr 1, 2008	Mar 1, 2013	Atherosclerosis
NCT00689416	Phase 1	Completed	Dec 1, 2007	Jun 1, 2009	Atherosclerosis
NCT00329758	Phase 2	Completed	Jul 1, 2006	Oct 1, 2007	Head Injury
NCT00355615	Phase 3	Completed	Jul 1, 2006	Jul 1, 2008	Familial Hypercholesterolemia
NCT00658463	Approved	Completed	Jan 1, 2006	Sep 1, 2007	Diabetes
NCT00800800	Phase 3	Completed	Nov 1, 2002	Sep 1, 2008	Aortic Stenosis

Competing Products

20 competing products in Atherosclerosis

See all competitors

Product	Company	Stage	Hype Score
Orforglipron + Placebo	Eli Lilly	Phase 3	77
Olmesartan medoxomil + Placebo	Daiichi Sankyo	Phase 3	77
Pactimibe sulfate	Daiichi Sankyo	Phase 2/3	65
Pactimibe	Daiichi Sankyo	Phase 2	52
Bempedoic acid + Ezetimibe + Rosuvastatin + Atorvastatin	Daiichi Sankyo	Phase 3	77
Micronized 17B-estradiol	Johnson & Johnson	Phase 2/3	65
Rosuvastatin + placebo + aspirin + placebo	AstraZeneca	Approved	85
Rosuvastatin + Placebo	AstraZeneca	Approved	85
rosuvastatin + placebo	AstraZeneca	Phase 1	33
Rosuvastatin + Placebo	AstraZeneca	Phase 1	33
Rosuvastatin + Atorvastatin	AstraZeneca	Phase 3	77
Rosuvastatin (5mg，10mg，20mg) + Rosuvastatin 5mg	AstraZeneca	Approved	85
Vorapaxar + Placebo	Merck	Phase 3	77
Vorapaxar + Placebo + Aspirin + Clopidogrel	Merck	Phase 2	52
Niacin/simvastatin compared to simvastatin alone at 2 doses	Merck	Approved	85
lovastatin	Merck	Phase 2/3	65
Ezetimibe + Placebo	Merck	Approved	85
Vorapaxar + Placebo	Merck	Phase 3	77
Niaspan	Merck	Pre-clinical	23
MK0633	Merck	Phase 2	52

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved